02.06.2024, 1849 Zeichen

Valneva: Valneva, a specialty vaccine company, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The European Commission (EC) will review the CHMP recommendation, and a decision on the marketing authorization application of IXCHIQ^® in the European Union (EU), Norway, Liechtenstein and Iceland is expected in the third quarter of 2024. If approved, it will become the first chikungunya vaccine available in Europe to address this unmet medical need. In accordance with the International Reliance Procedure (IRP), Valneva is also preparing a Marketing Authorization Application (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA). Juan Carlos Jaramillo, Chief Medical Officer of Valneva, commented, “This positive CHMP opinion marks a crucial milestone toward introducing a preventative solution against chikungunya in the EU. In recent years, climate change has caused the Aedes mosquito, a known carrier of chikungunya and dengue viruses, to spread to areas in Europe that were previously unaffected. It is critical to provide a vaccine solution not only to European travelers going to endemic chikungunya areas, such as South America or Africa, but also to the local European populations experiencing invasive mosquito attacks. The broader we can make this vaccine accessible, the better we will mitigate the burden of this debilitating illness, and we would like to thank our partner, CEPI, for supporting us in this endeavor.”
Valneva: weekly performance: 6.03%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (31/05/2024)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1202: ATX unverändert, der IPO-Index trudelt und ist die Addiko-Geschichte wirklich schon gegessen?

Bildnachweis

Aktien auf dem Radar:Frequentis, Zumtobel, AT&S, Austriacard Holdings AG, Polytec Group, Rosenbauer, Verbund, OMV, voestalpine, Porr, Fabasoft, Heid AG, Reploid Group AG, Marinomed Biotech, Wolftank-Adisa, Wiener Privatbank, BKS Bank Stamm, Wolford, Amag, Bawag, EuroTeleSites AG, CPI Europe AG, Österreichische Post, Telekom Austria, UBM, SAP, Fresenius Medical Care, Münchener Rück, MTU Aero Engines, Deutsche Bank, Volkswagen Vz..

---